Knowledge Hub

US Allergic Rhinitis industry Drug Forecast, Trends, Regulations , Competitive Landscape and Analysis to 2024

Press Release   •   Oct 24, 2016 05:34 EDT

AR is becoming an increasingly prevalent condition, with the most common form being moderate to severe in nature (Baena-Cagnani et al., 2015). According to the European Academy of Allergy and Clinical Immunology (EAACI), 50% of Europeans will suffer from an allergy by 2027 (Papadopoulos et al., 2012). The Allergic Rhinitis (AR) market has declined very slowly over the past decade, as has it become saturated with relatively efficacious standard therapies, such as antihistamines (AHs), intranasal corticosteroids (INCS), and leukotriene receptor antagonists (LRAs), and has also been facing increasing generic competition. Despite the rising prevalence of AR, and a large patient population that is dissatisfied with the current treatment options, the market size for symptomatic therapies alone is set to shrink, as the remaining branded products lose patent protection. There is an increasing shift in the transfer of prescription AR products to over-the-counter (OTC) status, which is driving patients to pharmacies rather than to physicians, further diluting the prescription AR market. The immense, crowded generic AR market has been largely unappealing to drug manufacturers. Consequently, only two symptomatic therapies are expected to launch before 2024.

In 2014, the base year of the forecast period, AR sales in the US were around $2.8 billion. As in the global markets, this decrease will be fueled mainly by the patent expiries of numerous INCS, and the launch of the first OTC INCS in US pharmacies. Despite the fact that the prevalence of AR patients is set to increase over the forecast period, only one drug will be launched during this time, which is expected to face stiff competition upon entry and capture little market share.

Get Sample Copy Of This Report At :


- Overview of Allergic Rhinitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Allergic Rhinitis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Allergic Rhinitis.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in the US.

Follow us on LinkedIn:

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 10

3 Disease Overview 11

3.1 Etiology and Pathophysiology 11

3.2 Symptoms 14

3.3 Classification 15

3.3.1 Seasonal and Perennial AR 15

3.3.2 ARIA Classification of AR 15

3.4 Diagnosis 16

3.5 Quality of Life 18

4 Disease Management 19

4.1 Diagnosis and Treatment Overview 19

4.1.1 Diagnosis 19

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20

4.1.3 Clinical Practice 23

4.2 US 32

5 Competitive Assessment 35

5.1 Overview 35

5.2 Oral H1 Antihistamines 39

5.2.1 Overview 39

5.2.2 Efficacy 48

5.2.3 Safety 49

5.2.4 SWOT Analysis 51

5.2.5 Forecast 52

5.3 Intranasal Antihistamines 52

5.4 Intranasal Corticosteroids 55

5.4.1 Overview 55

5.4.2 Efficacy 62

5.4.3 Safety 64

5.4.4 SWOT Analysis 65

5.4.5 Forecast 66

5.5 Combination Intranasal Corticosteroids/Antihistamines 66

5.5.1 Dymista 66

5.6 Decongestants 75

5.6.1 Overview 75

5.7 Intranasal Anticholinergics 78

5.7.1 Overview 78

5.8 Leukotriene Receptor Antagonists 79

5.8.1 Overview 79

5.9 Cromones 82 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.